Revenue cycle management solutions provider MBX Medical Billing Experts has rolled out a new healthcare data analytics tool aimed at helping provider organizations maximize financial and operational ...

MBX Biosciences, Inc. (MBX) closed the last trading session at $24.07, gaining 74.8% over the past four weeks, but there ...

CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

MBX 1416 showed a favorable safety profile in Phase 1 trials, with no dose-related serious adverse events and mild to moderate side effects. The drug demonstrated a 90-hour half-life, supporting ...

MBX Biosciences (MBX) announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company’s parathyroid hormone peptide prodrug in development for ...

Company is the third biotech to set price ranges for planned deals since Friday MBX Biosciences (MBX), a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, ...

MBX Biosciences, a Carmel startup that has raised an eye-popping $150 million in venture funding, has received clearance from federal regulators to move its second experimental drug into human testing ...

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to ...

(RTTNews) - MBX Biosciences, Inc. (MBX), announced Monday that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for MBX 4291, its long-acting GLP-1/GIP ...